As expected, behavioral experiments showed that BX795 (10 μg), anti-IFN-α (300 ng) and anti-IFN-β (300 ng) entirely compensated the therapeutic effects of DMXAA on morphine-induced itch (Fig. 6C), AEW-induced itch (Fig. 6D), and DCP-induced itch (Fig. 6E), manifesting that TBK1-dependent IFN-I response is a critical step for the alleviation of opioid-induced acute itch and dermatitis-induced chronic itch by STING agonism. Here, TBK1 is linked to dermatitis.